MSD secures victory before English court
20-10-2020
Australian court issues mixed vaccine patent ruling
15-10-2020
Biogen loses another battle over MS drug patent
21-09-2020
Fed Circuit rejects Biogen’s plea in MS drug dispute
23-04-2020
Repelsteeltje / Shutterstock.com
The US Court of Appeals for the Federal Circuit has sided with EMD Serono and Pfizer over the invalidation of a multiple sclerosis (MS) drug patent, in a defeat for biotech company Biogen.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Pfizer, Merck KGaA, Biogen, EMD Serono, Federal Circuit, multiple sclerosis, patent infringement, patent invalidation
